Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27187327 | 0.88 | ALDH1A1 (0.51) | ALDH1A1TSHRSMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL8757353 | 0.88 | ALDH1A1 (0.51) | ALDH1A1TSHRSMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL52770 | 0.83 | TSHR (0.51) | ALDH1A1TSHRSMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL17064719 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4139139 | 0.79 | NPSR1 (0.44) | ALDH1A1TSHRSMN1; SMN2TBXAS1 | |
| SCHEMBL27517126 | 0.78 | MEN1 (0.54) | ALDH1A1TSHRSMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL12820596 | 0.78 | TDP1 (0.45) | ALDH1A1TSHRMEN1KMT2APOLB | |
| SCHEMBL27416180 | 0.77 | SMN1; SMN2 (0.56) | ALDH1A1TSHRSMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL3747191 | 0.76 | TSHR (0.48) | ALDH1A1TSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10666125 | 0.76 | POLB (0.49) | ALDH1A1TSHRSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2019-05-23 | — | — | US | disclosed |
| WO-2017200984-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-1340762-B1 | Cephalosporin synthesis | SANDOZ AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| EP-1340762-A1 | Cephalosporin synthesis | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2003-09-03 | — | — | EP | disclosed |
| EP-0757691-B1 | CEPHALOSPORIN SYNTHESIS | BIOCHEMIE GMBH (AT) | 2003-07-02 | — | — | EP | disclosed |
| US-6093813-A | Cephalosporin compounds | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2000-07-25 | — | — | US | disclosed |
| US-6063917-A | Cephalosporin synthesis | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2000-05-16 | — | — | US | disclosed |
| US-6034237-A | 3-imino-cephalosporins | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2000-03-07 | — | — | US | disclosed |
| US-5856474-A | Cephalosporin synthesis | BIOCHEMIE GESELLSCHAFT, M.B.H. (AT) | 1999-01-05 | — | — | US | disclosed |
| EP-0647606-B1 | Derivatives of fullerene, process for their preparation and their use | HOECHST AG (DE) | 1997-03-26 | — | — | EP | disclosed |
| EP-0757691-A1 | CEPHALOSPORIN SYNTHESIS | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995029182-A1 | CEPHALOSPORIN SYNTHESIS | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1995-11-02 | — | — | WO | disclosed |
| EP-0647606-A1 | Derivatives of fullerene, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MYLK2, FKBP1B | ALDH1A1 2805/4885TSHR 4178/4885SMN1; SMN2 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.